Page 21 - Commercial Underwriting Mandates & Guidelines Binder Addendum

Annexure A: Treaty Exclusions
4.10.30.3 Creutzfeldt-Jacob Disease (CJD) variant Creutzfeldt-Jacob Disease (vCJD) or new variant Creutzfeldt-Jacob Disease (nvCJD)
4.10.30.4 Lipobay and/or Baycol
4.10.31 Lotronex
4.10.32 Paxil and/or Seroxat
4.11 Pharmaceutical/Medical Risks (Version 2014/2015)
Excluded are the below mentioned risks (parent companies) including their worldwide subsidiaries:
1 ABBOTT LABORATORIESi USA
2 AbbVie USA
3 ACTAVIS Inc.ii Iceland
4 ACTELION PHARMACEUTICALS Switzerland
5 ALLERGAN USA
6 AMGENiii USA
7 ASTELLAS Japan
8 ASTRAZENECA (including former MedImmune) UK
9 BAXTER INTERNATIONAL USA
10 BAYER (including former Schering AG)
11 BIOGEN IDEC USA
12 BIOMET USA
13 BOEHRINGER INGELHEIM Germany
14 BOSTON SCIENTIFIC CORPORATION (including former Guidant) USA
15 C.R. Bard USA
16 BRISTOL-MYERS SQUIBB USA
17 CELGENE USA
18 COVIDIEN (former TYCO Healthcare) Ireland
19 CSL Australia
#
Company Name
Headquarter location
Germany
20 DAIICHI SANKYO (former Daiichi Pharmaceutical and Sankyo Co.)
21 DAINIPPON SUMITOMO PHARMA (former Dainippon Pharmaceutical and Sumitomo Pharmaceutical including acquired Sepracor)
Japan Japan
22 DR. REDDY'S LABORATORIES
23 EDWARDS LIFESCIENCES
24 EISAI Japan
25 ENDO International Plc Ireland
26 FOREST LABORATORIESiv USA
27 GENERAL ELECTRIC Healthcare USA
28 GILEAD SCIENCES USA
29 GLAXOSMITHKLINE UK
30 GRIFOLS (including former Talecris Biotherapeutics) SPAIN
31 HOSPIRA USA
India USA
32 IPSEN (Beaufour Ipsen)
33 JOHNSON & JOHNSON (including former Synthes)
34 KCI LifeCell
France USA USA
Commercial Underwriting Mandates & Guidelines Addendum – Binder – Version 4 2022
18